Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Cantargia AGM Information 2020

Oct 13, 2020

3022_rns_2020-10-13_b0ee58e2-89f4-4bbe-b9d2-9d4236213cbd.pdf

AGM Information

Open in viewer

Opens in your device viewer

Press release

Cantargia AB 556791-6019 2020-10-13

Extraordinary general meeting in Cantargia AB (publ)

The extraordinary general meeting in Cantargia on 13 October 2020 resolved in accordance with the following:

  • to elect Flavia Borellini as new board member of the company.
  • that remuneration to Flavia Borellini shall be paid with USD 25,000 (or the equivalent amount in SEK) per year. In addition, a remuneration of USD 20,000 (or the equivalent amount in SEK) per year shall be paid to Flavia Borellini for her chairmanship and work in a Drug Development Committee, to be established by the company.
  • to issue not more than 1,900,000 warrants and approve that the company, directly or indirectly, transfers warrants and/or shares to the participants in the employee option program which was resolved on by the 2020 annual general meeting (Employee Option Program 2020/2023).

For more information on the new board member and the warrants, refer to the notice to the meeting.

For further information, please contact Göran Forsberg, CEO Telephone: +46 (0)46-275 62 60 E-mail: [email protected]

About Cantargia

Cantargia AB (publ), reg. no. 556791-6019, is a biotechnology company that develops antibody-based treatments for lifethreatening diseases. The basis for this is the protein IL1RAP that is involved in a number of diseases and where Cantargia has established a platform. The main project, the antibody CAN04, is being studied in the clinical phase I/IIa CANFOUR study with a primary focus on non-small cell lung cancer and pancreatic cancer. The study is focused on combination therapies, but also includes a monotherapy arm. Positive interim data from the combination therapies were presented in December 2019. Cantargia's second project, the antibody CAN10, addresses treatment of serious autoimmune/inflammatory diseases, with initial focus on systemic sclerosis and myocarditis.

Cantargia is listed on Nasdaq Stockholm (ticker: CANTA). More information about Cantargia is available at http://www.cantargia.com.